Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Benitec Biopharma (BNTC) Cash & Equivalents (2019 - 2025)

Benitec Biopharma has reported Cash & Equivalents over the past 7 years, most recently at $188.8 million for Q4 2025.

  • Quarterly results put Cash & Equivalents at $188.8 million for Q4 2025, up 141.18% from a year ago — trailing twelve months through Dec 2025 was $188.8 million (up 141.18% YoY), and the annual figure for FY2025 was $97.7 million, up 92.16%.
  • Cash & Equivalents reached $188.8 million in Q4 2025 per BNTC's latest filing, up from $94.5 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $188.8 million in Q4 2025 and bottomed at $2.5 million in Q2 2023.
  • Median Cash & Equivalents over the past 5 years was $19.8 million (2021), compared with a mean of $44.0 million.
  • The largest annual shift saw Cash & Equivalents crashed 79.45% in 2022 before it surged 1953.53% in 2024.
  • Over 5 years, Cash & Equivalents stood at $12.3 million in 2021, then fell by 14.83% to $10.5 million in 2022, then soared by 94.04% to $20.4 million in 2023, then surged by 284.23% to $78.3 million in 2024, then surged by 141.18% to $188.8 million in 2025.
  • Business Quant data shows Cash & Equivalents for BNTC at $188.8 million in Q4 2025, $94.5 million in Q3 2025, and $97.7 million in Q2 2025.